Kriya Therapeutics

Kriya Therapeutics is a well-funded, clinical-stage gene therapy company targeting large-market, chronic diseases in ophthalmology, metabolic disorders, and neurology. The company has raised over $900 million, including a $320 million Series D in late 2025, to advance its pipeline and internal manufacturing platform. Led by an experienced team with recent key C-suite appointments, Kriya aims to redefine gene therapy by addressing conditions with high unmet need that impact millions of patients.

Integrated gene therapy platform encompassing product design, research & development, and proprietary manufacturing, targeting validated biological pathways for common chronic diseases.

Kriya competes in crowded therapeutic areas (ophthalmology, metabolic disease) against large pharmaceutical companies and well-funded biotechs using a variety of modalities. In gene therapy specifically, it faces competition from other firms also expanding into common diseases. Its key differentiator is its explicit mission for broad accessibility and its fully integrated platform approach.